Table of Contents Author Guidelines Submit a Manuscript
International Journal of Analytical Chemistry
Volume 2009, Article ID 768743, 12 pages
http://dx.doi.org/10.1155/2009/768743
Research Article

A Multidisciplinary Investigation to Determine the Structure and Source of Dimeric Impurities in AMG 517 Drug Substance

1Department of Analytical Research and Development, Amgen Inc., Thousand Oaks, CA 91320, USA
2Genentech Inc., One DNA Way, Mail Stop 432A, South San Francisco, CA 94080, USA
3Chemical Process Research and Development Department, Amgen Inc., Thousand Oaks, CA 91320, USA

Received 27 August 2008; Accepted 10 October 2008

Academic Editor: Peter L. Rinaldi

Copyright © 2009 Maria Victoria Silva Elipe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Q3A(R2): Impurities in New Drug Substances,” ICH Harmonized Tripartite Guideline.
  2. F. Qiu and D. L. Norwood, “Identification of pharmaceutical impurities,” Journal of Liquid Chromatography and Related Technologies, vol. 30, no. 5–7, pp. 877–935, 2007. View at Publisher · View at Google Scholar
  3. R. Nageswara Rao and V. Nagaraju, “An overview of the recent trends in development of HPLC methods for determination of impurities in drugs,” Journal of Pharmaceutical and Biomedical Analysis, vol. 33, no. 3, pp. 335–377, 2003. View at Publisher · View at Google Scholar
  4. A. Abdel-Magid and S. Caron, Fundamentals of Early Clinical Drug Development: From Synthesis Design to Formulation, John Wiley & Sons, New York, NY, USA, 2006.
  5. M. S. Lee, LC/MS Applications in Drug Development, John Wiley & Sons, New York, NY, USA, 2002.
  6. J. Ermer, “The use of hyphenated LC-MS technique for characterisation of impurity profiles during drug development,” Journal of Pharmaceutical and Biomedical Analysis, vol. 18, no. 4-5, pp. 707–714, 1998. View at Publisher · View at Google Scholar
  7. A. Kocijan, R. Grahek, and L. Zupančič-Kralj, “Identification of an impurity in pravastatin by application of collision-activated decomposition mass spectra,” Acta Chimica Slovenica, vol. 53, no. 4, pp. 464–468, 2006. View at Google Scholar
  8. N. Lindegårdh, F. Giorgi, B. Galletti et al., “Identification of an isomer impurity in piperaquine drug substance,” Journal of Chromatography A, vol. 1135, no. 2, pp. 166–169, 2006. View at Publisher · View at Google Scholar · View at PubMed
  9. Ch. Bharathi, Ch. S. Prasad, D. V. Bharathi et al., “Structural identification and characterization of impurities in ceftizoxime sodium,” Journal of Pharmaceutical and Biomedical Analysis, vol. 43, no. 2, pp. 733–740, 2007. View at Publisher · View at Google Scholar · View at PubMed
  10. B. C. M. Potts, K. F. Albizati, M. O'Neil Johnson, and J. P. James, “Application of LC-NMR to the identification of bulk drug impurities in GART inhibitor AG2034,” Magnetic Resonance in Chemistry, vol. 37, no. 6, pp. 393–400, 1999. View at Publisher · View at Google Scholar
  11. G. J. Sharman and I. C. Jones, “Critical investigation of coupled liquid chromatography-NMR spectroscopy in pharmaceutical impurity identification,” Magnetic Resonance in Chemistry, vol. 41, no. 6, pp. 448–454, 2003. View at Publisher · View at Google Scholar
  12. M. V. Silva Elipe, “Advantages and disadvantages of nuclear magnetic resonance spectroscopy as a hyphenated technique,” Analytica Chimica Acta, vol. 497, no. 1-2, pp. 1–25, 2003. View at Publisher · View at Google Scholar
  13. C. Szántay, Jr., Z. Béni, G. Balogh, and T. Gáti, “The changing role of NMR spectroscopy in off-line impurity identification: a conceptual view,” Trends in Analytical Chemistry, vol. 25, no. 8, pp. 806–820, 2006. View at Publisher · View at Google Scholar
  14. K. M. Alsante, P. Boutros, M. A. Couturier et al., “Pharmaceutical impurity identification: a case study using a multidisciplinary approach,” Journal of Pharmaceutical Sciences, vol. 93, no. 9, pp. 2296–2309, 2004. View at Publisher · View at Google Scholar · View at PubMed